Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)Poulam M. Patel, Alan Spatz, Uwe Trefzer et al.|European Journal of Cancer|2011Cited by 210
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCélèste Lebbé, Brigitte Dréno, Caroline Dutriaux et al.|Cancers|2020Cited by 47
Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossoverCélèste Lebbé, Brigitte Dréno, Caroline Dutriaux et al.|Annals of Oncology|2016Cited by 14